by Cal Strode | Apr 27, 2023
The first Science Huddle panel discussion of 2023, Cell & Gene Therapy: Maximizing Commercialization, delved into challenges keeping leaders in the cell and gene therapy (CGT) commercialization space up at night. Moderating the event was Dr. Christian K....
by Cal Strode | Mar 29, 2023
Few people have made bigger contributions to the Canadian regenerative medicine ecosystem than Dr. Peter Zandstra. He is co-founder of two companies advancing cutting-edge biotechnologies for therapeutic use (Notch Therapeutics and ExCellThera, both of which are...
by Cal Strode | Jan 5, 2023
In 2022, the UK’s Cell and Gene Therapy Catapult (aka CGT Catapult) celebrated its tenth anniversary (congratulations!) marking 10 years of accelerating innovation in cell and gene therapies (CGTs) in the UK. Much like CCRM, CGT Catapult was established as an...
by CCRM Australia | Dec 6, 2022
Bhavi Kadakia was an intern with CCRM Australia in 2020 and is currently employed at Novotech. In the health-care sector, translation and commercialization have traditionally been described as complex and requiring heavy investment. As such, it is imperative for...
Comments